Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis

Arthritis & Rheumatism

Volumn 32, Issue 6, 1989, Pages 677-681

  Wallace, Carol A ^a,b   Bleyer, W Archie ^a,b   Sherry, David D ^a,b   Salmonson, Kathy L ^a,b   Wedgwood, Ralph J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADOLESCENT; BLOOD TOXICITY; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN TOXICITY;

ADMINISTRATION, ORAL; ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSAMINASES;

EID: 0024337639     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/anr.1780320604     Document Type: Article

References (33)

1. Low dose pulse methotrexate therapy in rheumatoid arthritis
2. A controlled two‐centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
3. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study
4. Methotrexate in rheumatoid arthritis: indications, contraindications, efficacy, and safety
5. The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
6. The current status of methotrexate use in rheumatic disease
7. Acute renal failure due to concomitant action of methotrexate and indomethacin (letter)
8. Fatal interaction between methotrexate and naproxen (letter)
9. Clinical and pharmacokinetic evidence of a lifethreatening interaction between methotrexate and ketoprofen
10. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate
11. Baseline and follow‐up liver histology in rheumatoid arthritis patients receiving pulse methotrexate (abstract)
12. Low incidence of hepatotoxicity associated with long‐term, low‐dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio
13. Hepatotoxicity after long‐term methotrexate therapy
14. Methotrexate hepatotoxicity in children with leukemia
15. Transient acute hepatotoxicity of high‐dose methotrexate therapy during childhood
16. Is methotrexate carcinogenic? (letter)
17. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective‐prospective analysis
18. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors
19. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy
20. Effects of treatment on fertility in long‐term survivors of childhood or adolescent cancer
21. Methotrexate and fertility in men
22. Clinical pharmacology of antineoplastic drugs
23. Clinical pharmacokinetics of methotrexate in children
24. Enzymatic assay for methotrexate in serum and cerebrospinal fluid
25. The clinical pharmacology of methotrexate: new applications of an old drug
26. Clinical pharmacology and therapeutic drug monitoring of methotrexate
27. Preliminary criteria for clinical remission in rheumatoid arthritis
28. The effect of organic acids on renal clearance of methotrexate in man
29. Biochemical and pathophysiological rationale for amethopterin in psoriasis
30. Methotrexate levels: a guide to therapy?
31. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates
32. Measuring levels of methotrexate (letter)